Vaxcyte Inc (PCVX)

Apr 12, 2026

PCVX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 12, 2026

Apr 11, 2026

How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing - Stock Traders Daily

Apr 11, 2026

Apr 10, 2026

Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump? - Yahoo Finance

Apr 10, 2026

Apr 10, 2026

What is the target price for Vaxcyte Inc stock2026 Momentum Check & AI Forecasted Entry/Exit Points - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

PCVX SEC FilingsVaxcyte, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 09, 2026

Apr 09, 2026

Vaxcyte CAO Sells $180,000 in Company Stock - National Today

Apr 09, 2026

Apr 08, 2026

Vaxcyte CAO Sells $180,000 in Stock - National Today

Apr 08, 2026

Apr 08, 2026

Vaxcyte (PCVX) finance chief sells 3,000 shares after option exercise - Stock Titan

Apr 08, 2026

Apr 08, 2026

Vaxcyte to Present at Annual Healthcare Conference - National Today

Apr 08, 2026

Apr 08, 2026

Vaxcyte Inc stock: Why its pneumococcal vaccine pipeline draws investor focus - AD HOC NEWS

Apr 08, 2026

Apr 08, 2026

Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference - Sahm

Apr 08, 2026

Apr 07, 2026

Elvia Cowan registers 3,000-share sale (PCVX) after option exercise - Stock Titan

Apr 07, 2026

Apr 06, 2026

Vaxcyte (PCVX) Stock Analysis Report | Financials & Insights - Benzinga Japan

Apr 06, 2026

Apr 05, 2026

Aberdeen Group plc Increases Holdings in Vaxcyte, Inc. $PCVX - MarketBeat

Apr 05, 2026

Apr 04, 2026

PCVX.O Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 04, 2026

PCVX Should I Buy - Intellectia AI

Apr 04, 2026

Apr 03, 2026

Insider Sell Alert: Jim Wassil Sells 2,250 Shares of Vaxcyte Inc (PCVX) - GuruFocus

Apr 03, 2026

Apr 03, 2026

Vaxcyte (PCVX) COO sells 2,250 shares in planned Rule 10b5-1 trades - Stock Titan

Apr 03, 2026

Apr 01, 2026

James Wassil sells 7,395 PCVX shares (NASDAQ: PCVX) - Stock Titan

Apr 01, 2026

Apr 01, 2026

Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat

Apr 01, 2026

Apr 01, 2026

Aug Ideas: Is now the right time to enter Vaxcyte Inc2026 Short Interest & Trade Opportunity Analysis Reports - baoquankhu1.vn

Apr 01, 2026

Mar 31, 2026

(PCVX) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Mar 31, 2026

Mar 31, 2026

Vaxcyte joins elite club of stocks with RS ratings over 90 - msn.com

Mar 31, 2026

Mar 30, 2026

Certain Common Stock of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener

Mar 30, 2026

Mar 30, 2026

Certain Pre-funded warrants of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com

Mar 30, 2026

Mar 30, 2026

Certain Restricted Stock Units of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - marketscreener.com

Mar 30, 2026

Mar 30, 2026

Certain Options of Vaxcyte, Inc. are subject to a Lock-Up Agreement Ending on 31-MAR-2026. - MarketScreener

Mar 30, 2026

Mar 30, 2026

Should Vaxcyte’s (PCVX) Fully Enrolled VAX-31 Phase 3 Trials Prompt a Portfolio Reassessment? - simplywall.st

Mar 30, 2026

Mar 27, 2026

Vanguard disaggregates holdings; PCVX ownership shown as 0 (PCVX) - stocktitan.net

Mar 27, 2026

Mar 26, 2026

Portfolio Update: Can Vaxcyte Inc continue delivering strong returns2026 Market WrapUp & Long Hold Capital Preservation Tips - baoquankhu1.vn

Mar 26, 2026

Mar 26, 2026

Assenagon Asset Management S.A. Increases Position in Vaxcyte, Inc. $PCVX - MarketBeat

Mar 26, 2026

Mar 25, 2026

Calif. Biotech Firm Vera Taps Vaxcyte Ex-GC As New CLO - Law360

Mar 25, 2026

Mar 24, 2026

Vaxcyte completes enrollment in two Phase 3 trials for VAX-31 - Investing.com Canada

Mar 24, 2026

Mar 23, 2026

Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults - Investing News Network

Mar 23, 2026

Mar 23, 2026

Vaxcyte (PCVX) Completes Enrollment for Key Phase 3 Trials - GuruFocus

Mar 23, 2026

Mar 21, 2026

Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative - simplywall.st

Mar 21, 2026

Mar 20, 2026

Assessing Vaxcyte (PCVX) Valuation After Strong VAX 31 Phase 1/2 Results In The Lancet - simplywall.st

Mar 20, 2026

Mar 20, 2026

Responsive Playbooks and the PCVX Inflection - Stock Traders Daily

Mar 20, 2026

Mar 20, 2026

Vaxcyte Announces Significant Development of First-of-Its-Kind PCV31 - Drug Topics

Mar 20, 2026

Mar 20, 2026

PCVX PE Ratio & Valuation, Is PCVX Overvalued - Intellectia AI

Mar 20, 2026

Mar 20, 2026

JPMorgan Chase & Co. Acquires 366,266 Shares of Vaxcyte, Inc. $PCVX - MarketBeat

Mar 20, 2026

Mar 19, 2026

Vaxcyte, Inc.: Fundamental Analysis and Financial Ratings | 1PCVX | US92243G1085 - marketscreener.com

Mar 19, 2026

Mar 19, 2026

Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet - Investing.com Australia

Mar 19, 2026

Mar 19, 2026

Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCVX) - GuruFocus

Mar 19, 2026

Mar 19, 2026

Insider Sell: Elvia Cowan Sells 1,892 Shares of Vaxcyte Inc (PCV - GuruFocus

Mar 19, 2026

Mar 18, 2026

Vaxcyte publishes VAX-31 phase 1/2 study results in Lancet By Investing.com - Investing.com South Africa

Mar 18, 2026

Mar 18, 2026

Vaxcyte (PCVX) Advances VAX-31 Vaccine with Positive Study Resul - GuruFocus

Mar 18, 2026